A Study of Experimental Medication BMS-986235 in Healthy Subjects

• Status: Active, not recruiting
• Trial end date: 2021-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of experimental medication BMS-986235 in healthy subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Patients must be normal healthy volunteers as determined by no clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations

• Patients must have a body mass index (BMI) of 18 - 30 mg/kg2, inclusive

Exclusion Criteria:

• Patients that are pregnant

• Patient with any significant acute or chronic medical illness

• Patient with a current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption

• Patient with any surgery within 12 weeks of study treatment administration

• Patient with any gastrointestinal surgery that could impact upon the absorption of study drug

• Patient who donated blood to a blood bank or in a clinical study (except a screening visit) within 12 weeks of study drug administration (within 2 weeks for plasma only)

• Patient who received a blood transfusion within 12 weeks of study drug administration

Other protocol defined inclusion/exclusion criteria could apply